Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSNKY Daiichi Sankyo	$22.66 -4.6%	$24.70	$20.92 ▼ $42.48	$44.97B	N/A	190,981 shs	127,132 shs
MKKGY Merck KGaA	$25.41 +1.2%	$26.78	$24.32 ▼ $39.17	$16.23B	0.94	178,115 shs	117,135 shs
ONC BeOne Medicines	$247.08 -2.3%	$245.59	$141.31 ▼ $287.88	$27.69B	0.3	298,435 shs	230,772 shs
TAK Takeda Pharmaceutical	$14.75 -1.0%	$14.79	$12.60 ▼ $15.68	$47.41B	0.23	1.96 million shs	3.41 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSNKY Daiichi Sankyo	0.00%	-5.46%	-7.21%	-4.34%	-29.23%
MKKGY Merck KGaA	0.00%	-6.15%	-4.77%	-11.55%	-30.61%
ONC BeOne Medicines	0.00%	-8.59%	+6.72%	+0.32%	+25,277,999,900.00%
TAK Takeda Pharmaceutical	0.00%	-3.15%	+4.67%	-1.91%	+17.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DSNKY Daiichi Sankyo	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MKKGY Merck KGaA	3.2986 of 5 stars	0.0	5.0	2.5	0.0	1.1	0.0	3.1
ONC BeOne Medicines	2.4476 of 5 stars	3.5	0.0	0.0	0.0	2.8	1.7	0.6
TAK Takeda Pharmaceutical	0.7765 of 5 stars	0.0	3.0	1.7	0.0	1.9	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DSNKY Daiichi Sankyo	4.00	Strong Buy	N/A	N/A
MKKGY Merck KGaA	3.00	Buy	N/A	N/A
ONC BeOne Medicines	3.00	Buy	$319.00	29.11% Upside
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest MKKGY, TAK, DSNKY, and ONC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	DSNKY Daiichi Sankyo	Nomura Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$312.00 ➝ $311.00
5/8/2025	ONC BeOne Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$348.00 ➝ $350.00
4/28/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$312.00 ➝ $312.00
4/24/2025	ONC BeOne Medicines	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$334.00 ➝ $334.00
4/21/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$311.00 ➝ $317.00
4/16/2025	ONC BeOne Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/10/2025	ONC BeOne Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$348.00 ➝ $348.00
4/7/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$312.00
4/7/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy	$312.00
4/2/2025	TAK Takeda Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DSNKY Daiichi Sankyo	$12.39B	3.47	$1.20 per share	18.91	$5.61 per share	4.04
MKKGY Merck KGaA	$22.57B	0.73	$8.25 per share	3.08	$50.22 per share	0.51
ONC BeOne Medicines	$3.81B	7.10	N/A	N/A	$34.10 per share	7.25
TAK Takeda Pharmaceutical	$30.09B	1.56	$3.14 per share	4.69	$14.39 per share	1.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DSNKY Daiichi Sankyo	$1.95B	$1.03	22.00	20.79	1.42	15.65%	17.92%	8.61%	7/29/2025 (Estimated)
MKKGY Merck KGaA	$3.00B	$2.11	12.03	12.40	1.87	13.23%	9.61%	5.59%	8/7/2025 (Estimated)
ONC BeOne Medicines	-$644.79M	-$3.72	N/A	348.00	N/A	-9.40%	-7.55%	-4.42%	N/A
TAK Takeda Pharmaceutical	$712.33M	$0.22	67.03	8.94	N/A	2.36%	10.64%	5.14%	7/30/2025 (Estimated)

Latest MKKGY, TAK, DSNKY, and ONC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	MKKGY Merck KGaA	$0.50	$0.59	+$0.09	$0.59	$5.32 billion	$5.89 billion
5/8/2025	Q4 2025	TAK Takeda Pharmaceutical	$0.24	$0.16	-$0.08	-$0.21	$8.02 billion	$7.34 billion
5/7/2025	Q1 2025	ONC BeOne Medicines	-$0.71	$1.22	+$1.93	$0.01	$1.12 billion	$1.12 billion
4/25/2025	Q4 2025	DSNKY Daiichi Sankyo	N/A	$0.30	N/A	$0.30	N/A	$3.40 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DSNKY Daiichi Sankyo	N/A	N/A	N/A	N/A	N/A
MKKGY Merck KGaA	$0.34	1.34%	N/A	16.11%	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.27	1.83%	N/A	122.73%	N/A

Latest MKKGY, TAK, DSNKY, and ONC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/23/2025	MKKGY Merck KGaA		$0.3382	1.25%	4/29/2025	4/30/2025	5/7/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DSNKY Daiichi Sankyo	0.06	2.53	1.85
MKKGY Merck KGaA	0.23	1.31	0.83
ONC BeOne Medicines	0.05	1.96	1.71
TAK Takeda Pharmaceutical	0.57	1.01	0.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DSNKY Daiichi Sankyo	N/A
MKKGY Merck KGaA	0.10%
ONC BeOne Medicines	48.55%
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
DSNKY Daiichi Sankyo	N/A
MKKGY Merck KGaA	N/A
ONC BeOne Medicines	6.62%
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DSNKY Daiichi Sankyo	17,435	1.89 billion	N/A	Not Optionable
MKKGY Merck KGaA	62,557	646.21 million	N/A	Not Optionable
ONC BeOne Medicines	11,000	109.56 million	102.31 million	N/A
TAK Takeda Pharmaceutical	49,281	3.18 billion	3.18 billion	Optionable

MKKGY, TAK, DSNKY, and ONC Headlines

Recent News About These Companies

Inscription Capital LLC Invests $303,000 in Takeda Pharmaceutical Co. (NYSE:TAK)

June 19 at 4:21 AM | marketbeat.com

Wisner Baum: Ninth Circuit Affirms Actos RICO Class Action Certification Against Takeda and Eli Lilly

June 18 at 9:33 PM | kxan.com

Takeda Pharmaceutical Co. (NYSE:TAK) Shares Purchased by QRG Capital Management Inc.

June 18 at 4:23 AM | marketbeat.com

Trump rekindles pharmaceutical tariff threat, suggesting import duties could come 'very soon': Reuters

June 17 at 3:35 PM | fiercepharma.com

Class Status Upheld in Takeda, Eli Lilly RICO Suit Over Actos

June 17 at 5:30 AM | news.bloomberglaw.com

GAMMA Investing LLC Has $1.56 Million Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

June 15, 2025 | marketbeat.com

Sun Pharma announce major leadership shake-up, names Kirti Ganorkar as MD, Shanghvi steps into executive Chairman Role

June 14, 2025 | moneycontrol.com

Sun Pharma names Kirti Ganorkar as new managing director, Dilip Shanghvi to continue as chairman

June 13, 2025 | msn.com

Wealth Enhancement Advisory Services LLC Lowers Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

June 9, 2025 | marketbeat.com

Clean Yield Group Lowers Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

June 8, 2025 | marketbeat.com

Takeda CEO Christophe Weber faces opposition to board reelection

June 7, 2025 | asia.nikkei.com

Itochu working to support overseas pharma firms to fill Japan's drug gaps

June 4, 2025 | japantimes.co.jp

Takeda Reports Adcetris Combo Approved by EC for Hodgkin Lymphoma

June 4, 2025 | msn.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Bought by NBC Securities Inc.

June 4, 2025 | marketbeat.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Short Interest Up 33.3% in May

June 3, 2025 | marketbeat.com

Medicamen Biotech rallies after securing USFDA approval for Bortezomib injection

June 3, 2025 | business-standard.com

Rusfertide reduces blood draws, maintains hematocrit, eases symptoms in polycythemia vera

June 2, 2025 | healio.com

ASCO: Takeda and Protagonist release positive Phase III VERIFY study of rusfertide in polycythemia vera

June 2, 2025 | thepharmaletter.com

Legacy Wealth Asset Management LLC Buys 44,635 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

June 2, 2025 | marketbeat.com

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

June 1, 2025 | businesswire.com

Versant Capital Management Inc Purchases 23,166 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

June 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge
By Jeffrey Neal Johnson | June 4, 2025
View Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge
Applied Digital: Now the High-Stakes Race to Build Begins
By Jeffrey Neal Johnson | June 17, 2025
View Applied Digital: Now the High-Stakes Race to Build Begins
Lululemon, UNH, Enphase: Bad News, Good Opportunity?
By Thomas Hughes | June 17, 2025
View Lululemon, UNH, Enphase: Bad News, Good Opportunity?
Tankers, Takedowns & Air Taxis: Insiders Are Buying These 3 Names
By Leo Miller | June 10, 2025
View Tankers, Takedowns & Air Taxis: Insiders Are Buying These 3 Names
Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?
By Nathan Reiff | June 20, 2025
View Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?

MKKGY, TAK, DSNKY, and ONC Company Descriptions

Daiichi Sankyo OTCMKTS:DSNKY

$22.66 -1.08 (-4.56%)

As of 03:51 PM Eastern

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

Merck KGaA OTCMKTS:MKKGY

$25.41 +0.30 (+1.20%)

As of 03:51 PM Eastern

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.

BeOne Medicines NASDAQ:ONC

$247.08 -5.70 (-2.25%)

As of 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Takeda Pharmaceutical NYSE:TAK

$14.74 -0.16 (-1.04%)

Closing price 03:59 PM Eastern

Extended Trading

$15.13 +0.39 (+2.64%)

As of 06:57 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time